Loading clinical trials...
Loading clinical trials...
Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) e...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Shen Chun-Hong
NCT06019975 · Autoimmune Encephalitis
NCT07477015 · Autoimmune Encephalitis
NCT07158229 · NMDAR Autoimmune Encephalitis
NCT04806620 · Post-Acute COVID-19 Syndrome, ME/CFS, and more
NCT03993262 · Autoimmune Encephalitis
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions